One of the most frequently asked questions about Selank is how long its effects last and for how long the peptide remains active in the body. However, no human pharmacokinetic studies have been published to date that definitively determine Selank's half-life, its blood concentration profile, or its exact elimination time. Most available research has focused on its biological and neurological effects, rather than its pharmacokinetic properties.
However, it is known that Selank was designed to remain active longer than its natural precursor, tuftsin. The addition of the Pro-Gly-Pro sequence helps protect the peptide from rapid enzymatic degradation, allowing it to maintain its biological activity for a longer period compared to naturally occurring tuftsin peptides [1,2].
Experimental studies have shown that Selank can induce biological effects that persist beyond the administration period. For instance, animal studies examining anxiety-related behaviors demonstrated a sustained anxiolytic effect throughout the four-week treatment period, suggesting that regular administration may provide stable biological activity over time [3]. Research on GABA receptor modulation, neurotransmitter regulation, and BDNF expression also indicates that Selank may initiate secondary biological changes that last longer than the peptide itself remains in circulation [2,4].
Since formal pharmacokinetic studies are still lacking, it is currently impossible to accurately determine for how many hours or days Selank remains in the blood or tissues. For this reason, any specific claims regarding duration of action or half-life should be treated with caution if not supported by direct pharmacokinetic data in humans.
How Long Does Selank Stay in the Body?
Currently, no human studies have been published determining how long Selank remains detectable in the body. Like many other peptides, Selank likely undergoes enzymatic breakdown into smaller peptide fragments and amino acids after administration. However, the exact elimination time has not been definitively established in clinical studies.
It is also worth distinguishing the physical presence of the peptide from the duration of its biological effects. Even after Selank is metabolized, processes related to neurotransmitters, neurotrophic factors, stress response, and gene expression can persist for a longer time [2,4].
For this reason, researchers usually pay more attention to the duration of biological activity than to attempts to estimate the unconfirmed elimination time.
Selank Half-Life
The exact half-life of Selank has not yet been described in published scientific literature concerning humans. Unlike many approved pharmaceutical drugs, Selank has not undergone extensive pharmacokinetic studies as part of large international clinical programs.
However, it is known that it was intentionally modified to increase stability towards tuftsin. The addition of the Pro-Gly-Pro sequence was intended to slow down enzymatic degradation and prolong the peptide's biological activity [1]. No peer-reviewed study has currently reported a confirmed plasma half-life value.
Therefore, any numerical estimates of Selank's half-life available on the internet should be interpreted with caution if not supported by direct pharmacokinetic studies.
How quickly does Selank start working?
Selank's onset of action appears to depend on the specific biological effect being assessed. Some laboratory studies suggest that Selank may influence neurotransmitter systems and receptor activity relatively quickly after administration, while clinically significant benefits may develop over several days or weeks.
Studies analyzing the interaction of Selank with GABA receptors have shown direct modulation of GABAergic signaling pathways, suggesting that some neurochemical effects may occur shortly after administration [2]. Research on enkephalin metabolism has also shown that Selank can inhibit enzymes responsible for their breakdown, providing another mechanism for early biological effects to occur [5].
Clinical trials provide additional information. In studies involving individuals with generalized anxiety disorder and neurasthenia, Selank demonstrated measurable anxiolytic effects during therapy and achieved efficacy comparable to medazepam [6]. However, the study did not specify the exact onset of action measured in minutes or hours.
Animal studies provide further clues. In long-term anxiety models, a significant reduction in anxiety behaviors was observed as early as the second day of therapy, and the benefits persisted throughout the study period [3]. These results suggest that while some neurochemical changes may occur relatively quickly, more noticeable behavioral effects may develop with regular use.
Does Selank work immediately?
Current data do not indicate that Selank acts immediately in the same way as fast-acting sedatives. Unlike benzodiazepines, which directly bind to the benzodiazepine sites of GABA-A receptors and can induce rapid effects, Selank operates through broader neuroregulatory mechanisms involving GABA signaling, endogenous opioid peptides, neurotrophic factors, and immune system-related pathways [2,5].
Since these mechanisms rely on the body's regulatory and adaptive processes, some effects may develop gradually rather than causing an immediate and distinct reaction. Available data suggests that the benefits associated with Selank may increase with continued use.
How quickly does Selank work?
Based on current research, Selank appears to be able to influence neurochemical pathways relatively quickly after administration. However, results such as reduced anxiety, improved emotional balance, or support for cognitive functions may require regular use for several days or a longer observation period [2–6].
The exact time to onset of effects may vary depending on factors such as route of administration, dosage, duration of therapy, individual physiology, and the biological parameter being assessed. A universally accepted onset time has not been established.
Applications
Available research indicates that Selank was developed to provide greater stability than its natural precursor and may elicit biological effects that persist beyond the period of administration. However, the exact half-life, elimination time, and duration of peptide persistence in the body have not yet been fully characterized in human studies.
Current data suggest that Selank may influence neurochemical pathways relatively quickly, while more noticeable effects related to anxiety, stress resistance, and cognitive functions may develop gradually over time. Further pharmacokinetic and clinical studies will be needed to more accurately determine how long Selank remains active and how quickly its effects appear.
Disclaimer
This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or therapeutic recommendations. Selank remains a research peptide in many countries, and its pharmacokinetic properties have not yet been fully determined in human clinical trials. The information presented is a summary of findings from human, animal, and mechanistic studies and should not be interpreted as claims regarding the peptide's efficacy, duration of action, or period of activity.
For research purposes only: Selank products offered by Semax Polska are intended solely for laboratory and scientific research. They are not approved for human consumption, medical use, diagnosis, treatment, or disease prevention. All research materials should be used in accordance with applicable regulations and the principles of good laboratory practice.
References
[1] Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Antiviral Properties of Structural Fragments of the Peptide Selank. Doklady Biological Sciences, 431, 79–82. https://doi.org/10.1134/S0012496610020031
[2] Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. F. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[3] Czabak-Garbacz, R., Cygan, B., Wolański, Ł., & Kozlovsky, I. (2006). Influence of Long-Term Treatment with Tuftsin Analogue TP-7 on Anxiety-Phobic States and Body Weight. Pharmacological Reports, 58(4), 562–567. PMID: 16963804.
[4] Levitskaya, N. G., Andreeva, L. A., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal Administration of the Peptide Selank Regulates BDNF Expression in Rat Hippocampus In Vivo. Doklady Biological Sciences, 431, 79–82.
[5] Zozulya, A. A., Kost, N. V., Sokolov, O. Y., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Y. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274
[6] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/